课题基金 / 基金详情

Development of a novel therapy for treatment of Spinal Muscular Atrophy

Development of a novel therapy for treatment of Spinal Muscular Atrophy
开发治疗脊髓性肌萎缩症的新疗法
批准号:
203088
负责人:
Parks Robin J
金额:
$14.57万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2010
资助国家:
加拿大
项目状态:
已结题
起止时间:
2010-03-01 至 2012-03-01

项目摘要

项目成果

Parks Robin J的其他基金

相似基金

相关文献

中文摘要
翻译
脊髓性肌萎缩症(SMA)是一种影响新生儿和幼儿的毁灭性常染色体隐性遗传病。它是由存活运动神经元(SMN)蛋白水平降低引起的。虽然正常情况下在身体的所有细胞中表达,但减少了e
英文摘要
Spinal muscular atrophy (SMA) is a devastating autosomal recessive disorder affecting newborns and young children. It is caused by reduced levels of the survival motor neuron (SMN) protein. Although normally expressed in all cells of the body, reduced e
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
6th Ottawa International Conference on Neuromuscular Disease and Biology
  • 批准号:
    480782
  • 项目类别:
    Miscellaneous Programs
  • 资助金额:
    $1.09万
  • 财政年份:
    2023
  • 负责人:
    Parks Robin J
  • 依托单位:
Epigenetic Regulation of the Adenovirus Genome
  • 批准号:
    468931
  • 项目类别:
    Operating Grants
  • 资助金额:
    $50.71万
  • 财政年份:
    2022
  • 负责人:
    Parks Robin J
  • 依托单位:
Extracellular vesicles as a biomarker and therapeutic for Spinal Muscular Atrophy
  • 批准号:
    443250
  • 项目类别:
    Operating Grants
  • 资助金额:
    $69.94万
  • 财政年份:
    2021
  • 负责人:
    Parks Robin J
  • 依托单位:
Extracellular vesicles as a biomarker and therapeutic for Spinal Muscular Atrophy
  • 批准号:
    442958
  • 项目类别:
    Operating Grants
  • 资助金额:
    $7.29万
  • 财政年份:
    2020
  • 负责人:
    Parks Robin J
  • 依托单位:
海外基金